Pyrls
@pyrls.bsky.social
The Pyrls website & mobile app make drug information easy for 50,000+ clinicians and trainees!📱💻 | a Y Combinator company
FDA Approves CAPLYTA (lumateperone) as an Add-On for Major Depressive Disorder in Adults
#instapyrls #pharmacy #pharmacist #pharmacystudent #pharmacyschool #medicine #physician #physicianassistant #nurse #nursepractitioner #medicalschool #paschool #npschool #nursingpharmacology #NAPLEX #NCLEX #resi
#instapyrls #pharmacy #pharmacist #pharmacystudent #pharmacyschool #medicine #physician #physicianassistant #nurse #nursepractitioner #medicalschool #paschool #npschool #nursingpharmacology #NAPLEX #NCLEX #resi
November 7, 2025 at 1:55 PM
FDA Approves CAPLYTA (lumateperone) as an Add-On for Major Depressive Disorder in Adults
#instapyrls #pharmacy #pharmacist #pharmacystudent #pharmacyschool #medicine #physician #physicianassistant #nurse #nursepractitioner #medicalschool #paschool #npschool #nursingpharmacology #NAPLEX #NCLEX #resi
#instapyrls #pharmacy #pharmacist #pharmacystudent #pharmacyschool #medicine #physician #physicianassistant #nurse #nursepractitioner #medicalschool #paschool #npschool #nursingpharmacology #NAPLEX #NCLEX #resi
FDA Approves LINZESS (linaclotide) for Children Ages 7 Years and Older With IBS-C
November 6, 2025 at 2:25 PM
FDA Approves LINZESS (linaclotide) for Children Ages 7 Years and Older With IBS-C
Chemo Body: Chemotherapy Side Effects 💊
Free PDF download available on the Pyrls website or app 🔮
Free PDF download available on the Pyrls website or app 🔮
September 30, 2025 at 4:45 PM
Chemo Body: Chemotherapy Side Effects 💊
Free PDF download available on the Pyrls website or app 🔮
Free PDF download available on the Pyrls website or app 🔮
Updated Hypertension Pharmacotherapy Review and Chart 📊
Available in the Pyrls website or app 🔮
Available in the Pyrls website or app 🔮
September 23, 2025 at 6:00 PM
Updated Hypertension Pharmacotherapy Review and Chart 📊
Available in the Pyrls website or app 🔮
Available in the Pyrls website or app 🔮
New LEQEMBI (lecanemab-irmb) Formulation and Additional Monitoring Recommendations
September 4, 2025 at 2:31 PM
New LEQEMBI (lecanemab-irmb) Formulation and Additional Monitoring Recommendations
FDA Approves the First Generic Product for SAXENDA (liraglutide)
September 2, 2025 at 3:34 PM
FDA Approves the First Generic Product for SAXENDA (liraglutide)
FDA Approves VIZZ (aceclidine), an Eye Drop to Improve Near Vision in Adults with Presbyopia
August 3, 2025 at 4:00 PM
FDA Approves VIZZ (aceclidine), an Eye Drop to Improve Near Vision in Adults with Presbyopia
FDA Approves KERENDIA (finerenone) for Heart Failure With Left Ventricular Ejection Fraction ≥40%
July 15, 2025 at 3:42 PM
FDA Approves KERENDIA (finerenone) for Heart Failure With Left Ventricular Ejection Fraction ≥40%
FDA Approves TNKase (Tenecteplase) for Acute Ischemic Stroke in Adults
March 4, 2025 at 1:45 AM
FDA Approves TNKase (Tenecteplase) for Acute Ischemic Stroke in Adults
New ACC/AHA Acute Coronary Syndromes Guideline
February 28, 2025 at 3:52 PM
New ACC/AHA Acute Coronary Syndromes Guideline
We've made the following Pyrls Pro pharmacotherapy reviews and charts available free to all users to help ensure continued access to this information going forward!
February 11, 2025 at 5:59 PM
We've made the following Pyrls Pro pharmacotherapy reviews and charts available free to all users to help ensure continued access to this information going forward!
The Pyrls Diabetes Pharmacotherapy Review and Charts are currently being updated to reflect the 2025 ADA Standards of Care. Stay tuned!
January 2, 2025 at 1:00 AM
The Pyrls Diabetes Pharmacotherapy Review and Charts are currently being updated to reflect the 2025 ADA Standards of Care. Stay tuned!
ZEPBOUND (Tirzepatide) FDA-Approved for Obstructive Sleep Apnea ✨
December 20, 2024 at 11:21 PM
ZEPBOUND (Tirzepatide) FDA-Approved for Obstructive Sleep Apnea ✨
CDC Releases New 2025 Adult and Pediatric Immunization Schedules
November 25, 2024 at 6:51 PM
CDC Releases New 2025 Adult and Pediatric Immunization Schedules
Reposted by Pyrls
Excited to share our recent publication exploring a path forward to retire Cockroft Gault and move towards universal eGFR-based medication dosing decisions, a monumental effort led by Wendy St. Peter and the @nkf-professionals.bsky.social
doi.org/10.1093/ajhp...
doi.org/10.1093/ajhp...
November 18, 2024 at 8:26 PM
Excited to share our recent publication exploring a path forward to retire Cockroft Gault and move towards universal eGFR-based medication dosing decisions, a monumental effort led by Wendy St. Peter and the @nkf-professionals.bsky.social
doi.org/10.1093/ajhp...
doi.org/10.1093/ajhp...
